^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    TNF inhibitor

    Related drugs:
    4d
    CD: TNFi Plus Low-Dose Upadacitinib vs TNFi Intensification in Crohn's Disease With Suboptimal Response (clinicaltrials.gov)
    P4, N=312, Recruiting, Sixth Affiliated Hospital, Sun Yat-sen University
    New P4 trial
    |
    CRP (C-reactive protein)
    4d
    The Multifaceted Legacy of Thalidomide: Chemistry and Biology Driving Modern Drug Design. (PubMed, ChemMedChem)
    Beyond protein degradation, the diverse biological activities of thalidomide are discussed, including modulation of cytokines, angiogenesis, and immune signaling pathways. Collectively, thalidomide exemplifies how mechanistic insight, synthetic innovation and careful risk-benefit evaluation can transform a once-discarded molecule into a cornerstone of contemporary drug design.
    Review • Journal
    |
    CRBN (Cereblon)
    |
    lenalidomide • pomalidomide • thalidomide
    15d
    Preventing Structural Damage in Early Psoriatic Arthritis (clinicaltrials.gov)
    P4, N=108, Recruiting, Chinese University of Hong Kong
    New P4 trial
    23d
    MINDFuL: A Study of XPro1595 in Patients with Early Alzheimer's Disease with Biomarkers of Inflammation (clinicaltrials.gov)
    P2, N=201, Completed, Inmune Bio, Inc. | Active, not recruiting --> Completed
    Trial completion
    26d
    Glutamine Combined With Thalidomide in Preventing Radiation-induced Oral Mucositis (clinicaltrials.gov)
    P3, N=138, Completed, Air Force Military Medical University, China | Recruiting --> Completed
    Trial completion
    |
    thalidomide
    1m
    Current and emerging pharmacotherapies for treating vascular malformations. (PubMed, Expert Rev Clin Pharmacol)
    We discuss clinical evidence, limitations, and practical considerations for sirolimus, PI3K inhibitors, thalidomide, MEK inhibitors, and KRAS-directed agents, as well as emerging combination and intermittent strategies to balance efficacy and toxicity...Targeted therapies are shifting management from procedure-centered to biology-guided care. Future progress depends on standardized molecular testing, patient-centered outcomes, and optimized treatment duration to achieve durable disease control with acceptable long-term toxicity.
    Review • Journal
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    Mekinist (trametinib) • sirolimus • thalidomide
    1m
    An Open-Label Extension of XPro1595 in Patients With Alzheimer's Disease (clinicaltrials.gov)
    P2, N=11, Terminated, Inmune Bio, Inc. | Active, not recruiting --> Terminated; Sponsor resource allocation
    Trial termination
    1m
    Selenoprotein thioredoxin reductase 1 promotes cancer cells ferroptosis by suppressing GPX4 expression. (PubMed, Cell Death Differ)
    Mechanistically, the CRL4ACRBN E3 complex ubiquitinates KEAP1 at K84 and K312, driving KEAP1 degradation. CRBN inhibitor thalidomide and IKE combination treatment results in markedly retarded tumor progression. Our study reveals a crucial pro-ferroptotic role for TrxR1 and nominates it as a potential biomarker for guiding future ferroptosis-inducing therapies in select cancers.
    Journal
    |
    KEAP1 (Kelch Like ECH Associated Protein 1) • CRBN (Cereblon) • GPX4 (Glutathione Peroxidase 4)
    |
    thalidomide
    2ms
    A Study to Assess the Safety and Efficacy of Different Doses of ELV001 to Treat Active Rheumatoid Arthritis in Patients With an Inadequate Response to Methotrexate and Tumor Necrosis Factor Inhibition (START SYNERGY) (clinicaltrials.gov)
    P2, N=180, Not yet recruiting, Elevara Medicines Limited
    New P2 trial
    |
    CRP (C-reactive protein)
    2ms
    BDH-WM02: The Efficacy of TCD Following by TP Maintenance Therapy in Newly Diagnosed WM (clinicaltrials.gov)
    P4, N=44, Completed, Institute of Hematology & Blood Diseases Hospital, China | Unknown status --> Completed
    Trial completion
    |
    cyclophosphamide • prednisone • thalidomide
    2ms
    UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy (clinicaltrials.gov)
    P3, N=177, Active, not recruiting, University of Arkansas | Trial completion date: Aug 2026 --> Aug 2027 | Trial primary completion date: Aug 2026 --> Aug 2027
    Trial completion date • Trial primary completion date
    |
    cisplatin • bortezomib • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • thalidomide • melphalan
    2ms
    A case report: Guillain-Barré syndrome probably associated with TNF inhibitor in Blau syndrome (ChiCTR2500113873)
    P=N/A, N=1, Completed, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine; Shanghai Children's Medical Center, Shanghai Jiao Tong Universit
    New trial